BFNH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BFNH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BioForce Nanosciences Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.02.
BioForce Nanosciences Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.02.
BioForce Nanosciences Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.02.
During the past 3 years, the average EPS without NRIGrowth Rate was 87.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -24.10% per year.
During the past 13 years, BioForce Nanosciences Holdings's highest 3-Year average EPS without NRI Growth Rate was 87.30% per year. The lowest was -1593.90% per year. And the median was -79.60% per year.
The historical data trend for BioForce Nanosciences Holdings's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioForce Nanosciences Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | - | -9.72 | -0.02 | -0.02 | -0.02 |
BioForce Nanosciences Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -0.01 | - | - | - | -0.01 |
For the Packaged Foods subindustry, BioForce Nanosciences Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's PE Ratio distribution charts can be found below:
* The bar in red indicates where BioForce Nanosciences Holdings's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
BioForce Nanosciences Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-0.472 | - | 0) | / | 29.272 | |
= | -0.02 |
BioForce Nanosciences Holdings's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-0.114 | - | 0) | / | 29.272 | |
= | -0.00 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
BioForce Nanosciences Holdings (OTCPK:BFNH) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of BioForce Nanosciences Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Kaiser Kaiser | director, 10 percent owner, officer: Secretary/Acting CFO | 3419 VIRGINIA BEACH BLVD, UNIT 252, VIRGINIA BEACH VA 23452 |
Merle Ferguson | director, 10 percent owner, officer: CEO/President/Treasurer | 2020 GENERAL BOOTH BLVD., SUITE 230, VIRGINIA BEACH VA 23454 |
Susan Donohue | 10 percent owner | 19001 S. RICHFIELD AVE, #102, GREEN VALLEY AZ 85614 |
Michael D Dunham | director | 12000 W PARK PL, EFFECTIVE MANAGEMENT SYSTEMS INC, MILWAUKEE WI 53224 |
Gregory D Brown | officer: Chief Financial Officer | BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010-8098 |
Kerry M Frey | officer: Chief Operating Officer | BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010 |
Eric Henderson | director, 10 percent owner | BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010 |
Lawrence Marshall Gold | director | 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025 |
Jean-jacques Sunier | director | BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010 |
Societe Generale Asset Management Alternative Investments | 10 percent owner | 170, PLACE HENRI REGNAULT, LADEFENSE, PARIS I0 92043 |
Ed Cowle | 10 percent owner | 6 EAST 45TH ST., SUITE 1000, NEW YORK NY 10017 |
H Deworth Williams | 10 percent owner | 2681 EAST PARLEYS WAY, SUITE #204, SALT LAKE CITY UT 84109 |
Carter Robert P Iii | 10 percent owner | 25 RADCLIFFE DRIVE, VOORHEES NJ 08043 |
Harvey N Kaye | 10 percent owner | 190 NW SPANISH RIVER BLVD., SUITE 101, BOCA RATON FL 33431 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.